ReviewFEBS letters2026
Atomic force microscopy-based nanomechanical signatures as cancer biomarkers in a nutshell.
Review in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Atomic force microscopy-AFM enables label-free quantification of cellular and tissue mechanics with nanoscale resolution under near-physiological conditions, providing access to physical properties that are not captured by conventional approaches. In cancer, mechanical remodeling spans multiple scales, from cytoskeletal reorganization and increased cell deformability to extracellular matrix deposition and desmoplastic stiffening of solid tumors. These alterations generate reproducible nanomechanical fingerprints that distinguish cancer states at both the single-cell and tissue level. This review summarizes the principles underlying AFM, discusses their application in cancer diagnosis via tumor biopsy analysis, and highlights emerging efforts to extend mechanophenotyping toward circulating tumor-associated analytes in liquid biopsy. Finally, we illustrate the broader applicability of this framework using pulmonary fibrosis and discuss key challenges for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.